Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 5/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | JAK1 | P23458 | 3/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21522398 | 0.85 | KDM1A (0.53) | KDM1AMAOBBTKEPHX2CKS1B | |
| SCHEMBL22570115 | 0.85 | MERTK (0.45) | KDM1AMAOBBTKCKS1BSKP1 | |
| SCHEMBL22570099 | 0.85 | KDM1A (0.53) | KDM1AMAOBBTKEPHX2CKS1B | |
| SCHEMBL25042174 | 0.85 | MERTK (0.45) | KDM1AMAOBBTKCKS1BSKP1 | |
| SCHEMBL28483806 | 0.85 | MERTK (0.45) | KDM1AMAOBBTKCKS1BSKP1 | |
| SCHEMBL24220939 | 0.83 | MERTK (0.48) | KDM1AMAOBBTKCKS1BSKP1 | |
| SCHEMBL29361761 | 0.83 | MERTK (0.48) | KDM1AMAOBBTKCKS1BSKP1 | |
| SCHEMBL6458263 | 0.82 | JAK1 (0.43) | KDM1AMAOBBTKEPHX2CKS1B | |
| SCHEMBL6458275 | 0.82 | JAK1 (0.43) | KDM1AMAOBBTKEPHX2CKS1B | |
| SCHEMBL6460800 | 0.81 | JAK2 (0.45) | KDM1AMAOBBTKCKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12251387-B2 | Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-03-18 | — | — | US | disclosed |
| EP-3740479-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12121524-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-22 | — | — | US | disclosed |
| US-11813267-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813267-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230277547-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230277547-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3985003-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3985003-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3985003-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2019143675-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
| US-10258627-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180161336-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | US | disclosed |
| US-9987284-B2 | Substituted benzooxadiazole DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-05 | — | — | US | disclosed |
| US-20160354381-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160340341-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-24 | — | — | US | disclosed |
| US-9359380-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-07 | — | — | US | disclosed |
| US-9340557-B2 | Substituted quinoxaline DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-17 | — | — | US | disclosed |
| WO-2014159690-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275024-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277547-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | DTYMK, POLK, TOP1 | KDM1A 828/4885MAOB 1852/4885BTK 940/4885 |
| US-11813267-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | KDM1A 1124/4885MAOB 2973/4885BTK 916/4885 |
| US-12121524-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | KDM1A 1125/4885MAOB 3026/4885BTK 929/4885 |
| US-20180161336-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | KDM1A 1124/4885MAOB 2973/4885BTK 916/4885 |
| US-20160340341-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | KDM1A 1124/4885MAOB 2973/4885BTK 916/4885 |
| US-20140275024-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | KDM1A 1124/4885MAOB 2973/4885BTK 916/4885 |
| US-12251387-B2 | Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors | TOP1, TOP2A, TOP2B | KDM1A 457/4885MAOB 977/4885BTK 615/4885 |
| US-20160354381-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | KDM1A 1124/4885MAOB 2973/4885BTK 916/4885 |
| US-10258627-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | KDM1A 1124/4885MAOB 2973/4885BTK 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.